The role of positron emission tomography in the management of non-small cell lung cancer

Canadian Journal of Surgery

Volumn 52, Issue 3, 2009, Pages 235-242

  Behzadi, Abdollah ^a,b,e   Ung, Yee ^c   Lowe, Val ^d   Deschamps, Claude ^d  

^a Scarborough Hospital   (Tonga)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^d MAYO CLINIC   (United States)

^e NONE   (Tonga)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METASTASIS; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; REVIEW;

CARCINOMA, NON-SMALL-CELL LUNG; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 67649188611     PISSN: 0008428X     EISSN: 14882310     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. Yang P, Allen MS, Aubry MC, et al. Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest 2005;128:452-462 (Pubitemid 40994510)
2. Ung YC, Maziak DE, Vanderveen JA, et al.; Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care. 18Fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer: a systematic review. J Natl Cancer Inst 2007;99:1753-1767
3. Hatanaka M. Transport of sugar in tumor cell membranes. Biochim Biophys Acta 1974;355:77-104.
4. Nolop KB, Rhodes CG, Brudin LH, et al. Glucose utilization in vivo by human pulmonary neoplasms. Cancer 1987;60:2682-2689 (Pubitemid 17161799)
5. Rigo P, Paulus P, Kaschten BJ, et al. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med 1996;23:1641-1674
6. Zerhouni EA, Stitik FP, Siegelman SS, et al. CT of the pulmonary nodule: a cooperative study. Radiology 1986;160:319-327 (Pubitemid 16070633)
7. Ost D, Fein A. Evaluation and management of the solitary pulmonary nodule. Am J Respir Crit Care Med 2000;162:782-787
8. Marom EM, Sarvis S, Herndon JE II, et al. T1 lung cancers: sensitivity of diagnosis with fluorodeoxyglucose PET. Radiology 2002;223: 453-459 (Pubitemid 34454325)
9. Gould MK, Maclean CC, Kuschner WG, et al. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA 2001;285:914-924 (Pubitemid 32171553)
10. Fischer BM, Mortensen J, Hojgaard L. Positron emission tomography in the diagnosis and staging of lung cancer: a systematic, quantitative review. Lancet Oncol 2001;2:659-666 (Pubitemid 33085811)
11. Coleman RE. PET in lung cancer. J Nucl Med 1999;40:814-820 (Pubitemid 29210758)
12. Prauer HW, Weber WA, Romer W, et al. Controlled prospective study of positron emission tomography using the glucose analogue [18f]fluorodeoxyglucose in the evaluation of pulmonary nodules. Br J Surg 1998;85:1506-11. (Pubitemid 28502579)
13. Gupta NC, Maloof J, Gunel E. Probability of malignancy in solitary pulmonary nodules using fluorine-18-FDG and PET. J Nucl Med 1996;37:943-948 (Pubitemid 126447126)
14. Nomori H, Watanabe K, Ohtsuka T, et al. Evaluation of F-18 fluorodeoxyglucose (FDG) PET scanning for pulmonary nodules less than 3 cm in diameter, with special reference to the CT images. Lung Cancer 2004;45:19-27. (Pubitemid 38757828)
15. Lejeune C, Al Zahouri K, Woronoff-Lemsi MC, et al. Use of a decision analysis model to assess the medicoeconomic implications of FDG PET imaging in diagnosing a solitary pulmonary nodule. Eur J Health Econ 2005;6:203-214 (Pubitemid 41638843)
16. Detterbeck FC, Falen S, Rivera MP, et al. Seeking a home for a PET, part 1: defining the appropriate place for positron emission tomography imaging in the diagnosis of pulmonary nodules or masses. Chest 2004;125:2294-2299 (Pubitemid 38788202)
17. Gould MK, Sanders GD, Barnett PG, et al. Cost-effectiveness of alternative management strategies for patients with solitary pulmonary nodules. Ann Intern Med 2003;138:724-735 (Pubitemid 38139236)
18. Fletcher JW; for the VA SNAP Cooperative Studies Group. PET for the evaluation of solitary pulmonary nodules. J Nucl Med 2009 Jan.21 [Epub ahead of print].
19. Stumpe KD, Dazzi H, Schaffner A, et al. Infection imaging using whole-body FDG-PET. Eur J Nucl Med 2000;27:822-832. (Pubitemid 30456765)
20. Bicik I, Bauerfeind P, Breitbach T, et al. Inflammatory bowel disease activity measured by positron-emission tomography. Lancet 1997; 350:262. (Pubitemid 27312299)
21. Lewis PJ, Salama A. Uptake of fluorine-18-deoxyglucose in sarcoidosis. J Nucl Med 1994;35:1647-1649
22. Yasuda S, Shothsu A, Ide M, et al. High fluorine-18-deoxyglucose uptake in sarcoidosis. Clin Nucl Med 1996;21:983-984
23. Chen YK, Chen YL. Elevated F-18 FDG uptake in the thymus in Graves' disease. Clin Nucl Med 2003;28:142-143
24. Rudd JH, Warburton EA, Fryer TD, et al. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation 2002;105:2708-2711 (Pubitemid 34615139)
25. Aoki J, Watanabe H, Shinozaki T, et al. FDG PET of primary benign and malignant bone tumors: standardized uptake value in 52 lesions. Radiology 2001;219:774-777 (Pubitemid 32476270)
26. Kamel EM, Thumshirn M, Truninger K, et al. Significance of incidental 18F-FDG accumulations in the gastrointestinal tract in PET/CT: correlation with endoscopic and histopathologic results. J Nucl Med 2004;45:1804-1810 (Pubitemid 47618435)
27. Heyneman LE, Patz EF. PET imaging in patients with bronchioloalveolar cell carcinoma. Lung Cancer 2002;38:261-266 (Pubitemid 35341800)
28. Daniels CE, Lowe VJ, Aubry MC, et al. The utility of FDG-PET in the evaluation of carcinoid tumors presenting as pulmonary nodules. Chest 2007;131:255-260
29. Erasmus JJ, McAdams HP, Patz EF Jr, et al. Evaluation of primary pulmonary carcinoid tumors using FDG PET. AJR Am J Roentgenol 1998;170:1369-1373 (Pubitemid 28210961)
30. Torizuka T, Zasadny KR, Wahl RL. Diabetes decreases FDG accumulation in primary lung cancer. Clin Positron Imaging 1999;2:281-287
31. Gorenberg M, Hallett WA, O'Doherty MJ. Does diabetes affect [(18)F]FDG standardised uptake values in lung cancer? Eur J Nucl Med Mol Imaging 2002;29:1324-1327 (Pubitemid 44392213)
32. Bryant AS, Cerfolio RJ. The maximum standardized uptake values on integrated FDG-PET/CT is useful in differentiating benign from malignant pulmonary nodules. Ann Thorac Surg 2006;82:1016-1020 (Pubitemid 44246691)
33. Mountain CF, Dresler CM. Regional lymph node classification for lung cancer staging. Chest 1997;111:1718-1723 (Pubitemid 27260108)
34. Martini N, Kris MG, Ginsberg RJ. The role of multimodality therapy in locoregional non-small cell lung cancer. Surg Oncol Clin N Am 1997;6:769-791 (Pubitemid 27454671)
35. Vansteenkiste J, De Leyn P, Deneffe G, et al. Present status of induction treatment in stage IIIA-N2 non-small cell lung cancer: a review. The Leuven Lung Cancer Group. Eur J Cardiothorac Surg 1998;13:1-12. (Pubitemid 28114080)
36. Reed CE, Harpole DH, Posther KE, et al. Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable nonsmall cell lung cancer. J Thorac Cardiovasc Surg 2003;126:1943-1951 (Pubitemid 38020756)
37. Gould MK, Kuschner WG, Rydzak CE, et al. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a metaanalysis. Ann Intern Med 2003;139:879-892
38. Gonzalez-Stawinski GV, Lemaire A, Merchant F, et al. A comparative analysis of positron emission tomography and mediastinoscopy in staging non-small cell lung cancer. J Thorac Cardiovasc Surg 2003; 126:1900-1905 (Pubitemid 38020749)
39. Cerfolio RJ, Ojha B, Bryant AS, et al. The role of FDG-PET scan in staging patients with nonsmall cell carcinoma. Ann Thorac Surg 2003; 76:861-866 (Pubitemid 37100761)
40. Detterbeck FC, Falen S, Rivera MP, et al. Seeking a home for a PET, part 2: defining the appropriate place for positron emission tomography imaging in the staging of patients with suspected lung cancer. Chest 2004;125:2300-2308 (Pubitemid 38788203)
41. de Langen AJ, Raijmakers P, Riphagen I, et al. The size of mediastinal lymph nodes and its relation with metastatic involvement: a meta-analysis. Eur J Cardiothorac Surg 2006;29:26-29 (Pubitemid 41831343)
42. Quint LE, Tummala S, Brisson LJ, et al. Distribution of distant metastases from newly diagnosed non-small cell lung cancer. Ann Thorac Surg 1996;62:246-250 (Pubitemid 26239872)
43. Klein JS, Webb WR. The radiologic staging of lung cancer. The radiologic staging of lung cancer. J Thorac Imaging 1991;7:29-47.
44. Ettinghausen SE, Burt ME. Prospective evaluation of unilateral adrenal masses in patients with operable non-small-cell lung cancer. J Clin Oncol 1991;9:1462-1466
45. Erasmus JJ, Patz EF Jr, McAdams HP, et al. Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18Ffluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol 1997;168:1357-1360
46. Jana S, Zhang T, Milstein DM, et al. FDG-PET and CT characterization of adrenal lesions in cancer patients. Eur J Nucl Med Mol Imaging 2006;33:29-35. (Pubitemid 41785306)
47. Kumar R, Xiu Y, Yu JQ, et al. 18F-FDG PET in evaluation of adrenal lesions in patients with lung cancer. J Nucl Med 2004;45: 2058-2062 (Pubitemid 47611636)
48. Bury T, Barreto A, Daenen F, et al. Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer. Eur J Nucl Med 1998;25: 1244-1247 (Pubitemid 28446049)
49. Cheran SK, Herndon JE II, Patz EF Jr. Com© 2009 Canadian Medical Association.son of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer. Lung Cancer 2004;44:317-25.
50. Cheran SK, Herndon JE II, Patz EF Jr. Com© 2009 Canadian Medical Association.son of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer. Lung Cancer 2004;44:317-25. 50. Pagani JJ. Non-small cell lung carcinoma adrenal metastases. Computed tomography and percutaneous needle biopsy in their diagnosis. Cancer 1984;53:1058-1060
51. MacManus MP, Hicks RJ, Matthews JP, et al. High rate of detection of unsuspected distant metastases by pet in apparent stage III nonsmall-cell lung cancer: implications for radical radiation therapy. Int J Radiat Oncol Biol Phys 2001;50:287-293 (Pubitemid 32472257)
52. Kinkel K, Lu Y, Both M, et al. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. Radiology 2002;224:748-756 (Pubitemid 34919808)
53. Viney RC, Boyer MJ, King MT, et al. Randomized controlled trial of the role of positron emission tomography in the management of stage I and II non-small-cell lung cancer. J Clin Oncol 2004;22:2357-2362 (Pubitemid 41115392)
54. Lorent N, De Leyn P, Lievens Y, et al. Long-term survival of surgically staged IIIA-N2 non-small-cell lung cancer treated with surgical combined modality approach: analysis of a 7-year prospective experience. Ann Oncol 2004;15:1645-1653 (Pubitemid 39562605)
55. Weber WA, Petersen V, Schmidt B, et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 2003;21:2651-2657 (Pubitemid 46606307)
56. Cerfolio RJ, Bryant AS, Winokur TS, et al. Repeat FDG-PET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer. Ann Thorac Surg 2004;78:1903-1909 (Pubitemid 39556258)
57. Vansteenkiste JF, Stroobants SG, Dupont PJ, et al. Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: an analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol 1999;17:3201-3206 (Pubitemid 29470652)
58. Downey RJ, Akhurst T, Gonen M, et al. Preoperative F-18 fluorodeoxyglucose positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol 2004;22:3255-3260 (Pubitemid 41103680)
59. Higashi K, Ueda Y, Arisaka Y, et al. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. J Nucl Med 2002;43:39-45. (Pubitemid 34101186)
60. Bury T, Corhay JL, Duysinx B, et al. Value of FDG-PET in detecting residual or recurrent nonsmall cell lung cancer. Eur Respir J 1999; 14:1376-1380 (Pubitemid 30019536)
61. Hellwig D, Groschel A, Graeter TP, et al. Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2006;33:13-21. (Pubitemid 41785304)
62. Hicks RJ, Kalff V, MacManus MP, et al. The utility of (18)F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: impact on management and prognostic stratification. J Nucl Med 2001;42:1605-1613 (Pubitemid 33131318)
63. Cerfolio RJ, Bryant AS, Ojha B, et al. Improving the inaccuracies of clinical staging of patients with NSCLC: a prospective trial. Ann Thorac Surg 2005;80:1207-1213
64. De Wever W, Ceyssens S, Mortelmans L, et al. Additional value of PET-CT in the staging of lung cancer: com© 2009 Canadian Medical Association.son with CT alone, PET alone and visual correlation of PET and CT. Eur Radiol 2007; 17:23-32. (Pubitemid 46063025)
65. Lardinois D, Weder W, Hany TF, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 2003;348:2500-2507 (Pubitemid 36706537)
66. Antoch G, Saoudi N, Kuehl H, et al. Accuracy of whole-body dualmodality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: com© 2009 Canadian Medical Association.son with CT and PET. J Clin Oncol 2004;22:4357-4368 (Pubitemid 41185156)
67. Halpern BS, Schiepers C, Weber WA, et al. Presurgical staging of non-small cell lung cancer: positron emission tomography, integrated positron emission tomography/CT, and software image fusion. Chest 2005;128:2289-2297 (Pubitemid 41507571)
68. Keidar Z, Haim N, Guralnik L, et al. PET/CT using 18F-FDG in suspected lung cancer recurrence: diagnostic value and impact on patient management. J Nucl Med 2004;45:1640-1646 (Pubitemid 47618469)
69. Yap CS, Czernin J, Fishbein MC, et al. Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose positron emission tomography. Chest 2006;129:393-401. (Pubitemid 43289860)
70. Pal A, Glekas A, Doubrovin M, et al. Molecular imaging of EGFR kinase activity in tumors with 124I-labeled small molecular tracer and positron emission tomography. Mol Imaging Biol 2006;8:262-277 (Pubitemid 44446020)
71. Sandblom G, Sorensen J, Lundin N, et al. Positron emission tomography with C11-acetate for tumor detection and localization in patients with prostate-specific antigen relapse after radical prostatectomy. Urology 2006;67:996-1000. (Pubitemid 43956436)
72. Cho SY, Polster J, Engles JM, et al. In vitro evaluation of adenosine 5?-monophosphate as an imaging agent of tumor metabolism. J Nucl Med 2006;47:837-845 (Pubitemid 46768448)
73. Vansteenkiste JF, Stroobants SG. Positron emission tomography in the management of non-small cell lung cancer. Hematol Oncol Clin North Am 2004;18:269-288 (Pubitemid 38201560)
74. Tian M, Zhang H, Oriuchi N, et al. Com© 2009 Canadian Medical Association.son of 11C-choline PET and FDG PET for the differential diagnosis of malignant tumors. Eur J Nucl Med Mol Imaging 2004;31:1064-1072 (Pubitemid 39050172)
75. Lavrenkov K, Partridge M, Cook G, et al. Positron emission tomography for target volume definition in the treatment of non-small cell lung cancer. Radiother Oncol 2005;77:1-4. (Pubitemid 41503381)
76. Seemann MD, Schaefer JF, Englmeier KH. Virtual positron emission tomography/computed tomography-bronchoscopy: possibilities, advantages and limitations of clinical application. Eur Radiol 2007; 17:709-715 (Pubitemid 46252350)
77. Mah K, Caldwell CB, Ung YC, et al. The impact of 18FDG-PET on target and critical organs in CT based treatment planning of patients with poorly defined non-small cell lung carcinoma: a prospective study. Int J Radiat Oncol Biol Phys 2002;52:339-350 (Pubitemid 34172999)
78. Bradley J, Thorstad WL, Mutic S, et al. Impact of FDG-PET on radiation therapy volume delineation in non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2004;59:78-86. (Pubitemid 38501510)
79. Caldwell CB, Mah K, Ung YC, et al. Observer variation in contouring gross tumor volume in patients with poorly defined non-smallcell lung tumors on CT: the impact of 18FDG-hybrid PET fusion. Int J Radiat Oncol Biol Phys 2001;51:923-931 (Pubitemid 33026421)
80. Fox JL, Rengan R, O'Meara W, et al. Does registration of PET and planning CT images decrease interobserver and intraobserver variation in delineating tumor volumes for non-small-cell lung cancer? Int J Radiat Oncol Biol Phys 2005;62:70-75 (Pubitemid 40591925)